The tweet was deleted by the author.
But we saved everything 🙂.
BeOne Medicines, led by CEO John Oyler, has announced encouraging topline results from its Phase 2 study. The trial focused on their next-generation BCL2 inhibitor, a promising treatment for patients with relapsed or refractory mantle cell lymphoma.
This development represents a significant advancement for patients facing this challenging form of cancer. Oyler stated that the company remains committed to ''advancing science for patients'' and emphasized the importance of this milestone in the fight against difficult cancers.